Cyclerion Therapeutics Inc (CYCN) 13F Filing Data & Analysis (Q2 2026)

CYCN ranks #8287 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

21 institutions disclose a position in CYCN, but none treat it as a major bet — even Kalehua Capital Management LLC, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

Fidelity has added to its CYCN position for two straight quarters, increasing it by $2.2M to reach $2.2M today.

CYCN reported a net loss of $6.7M over the trailing twelve months.

• Not yet profitable — net loss of $6.7M over the trailing twelve months
• Revenue declined 12.6% year over year
• Net income declined year over year, from -$1.9M to -$6.7M
• Operating cash flow was negative, using $3.3M in cash
• Current ratio of 5.15x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting